The c -erbB -2 / neu -encoded protein p185 is closely related to the growth and metastasis of adenocarcinoma. We sought to reverse the malignant phenotype of gastric cancer cell line SGC7901 with c -erbB -2 -specific ribozyme. We designed the ribozyme and generated the in vitro transcription vectors of the ribozyme and its substrate. In vitro cleavage reaction indicated that the ribozyme catalyzed 79.3% target RNA in 1 hour at 378C. Then, we generated the eucaryotic expression vectors of the ribozyme and transfected them into SGC7901 cells, which highly express p185. Analyses showed that the c -erbB -2 mRNA and p185 were reduced remarkably in the ribozyme -transfected cells. The growth rate of the ribozyme -transfected cells was much lower than that of the control group. Tumorigenicity was also decreased dramatically in nude mice. The results demonstrated that c -erbB -2 -specific ribozyme may inhibit the malignancy of gastric cancer cells SGC7901. Cancer Gene Therapy ( 2001 ) 8, 835 -842 
T he c -erbB -2 proto -oncogene (also called HER -2 or neu) encodes a 185 -kDa transmembrane glycoprotein with intrinsic tyrosine kinase activity. 1 -3 It is a member of the growth factor receptor tyrosine kinase gene family and shares an extensive homology with the gene for epidermal growth factor receptor. 4 p185 is commonly expressed in fetal epithelium cells and at a low level in normal postnatal tissues. The overexpression and amplification of this gene can result in malignant transformation in some cell lines. 5 -7 Its overexpression or amplification is closely related to the growth and metastasis of adenocarcinomas such as breast cancer, gastrointestinal cancer, ovarian cancer, and prostate cancer. 8 -13 The high expression of p185 indicates a poor prognosis in these cancers. 14 -16 p185 has been a target of biotherapy in some cancers with p185 overexpression. In the early stage, p185 is targeted by immunotoxin or immunoliposome. 17, 18 Some researchers have reported that even anti -erbB2 monoclonal antibody alone can inhibit growth of the p185 overexpressed cancer cells. 19, 20 As new approaches to gene therapy have been developed, antisense c -erbB -2 has also been studied in experimental treatment of p185 overexpressed cancer cells. 21, 22 Most of these studies claimed satisfactory results and suggested that p185 may be a good target for gene therapy of these cancers.
As a kind of RNA with catalytic activity, ribozymes can cleave the target RNA in specific regions and can be reused in this process. 23, 24 Using ribozymes is now a more effective approach in gene therapy for cancers and viral infectious diseases. 25, 26 In our study, we probed the effect of c-erbB -2 -specific ribozyme that we designed in the reversion of the malignant phenotype of gastric cancer cell line SGC7901.
MATERIALS AND METHODS

Cell lines
SGC7901, an adenocarcinoma gastric cancer cell line, was obtained from Dr. X.W. Feng (Academy of Military Medical Science, Beijing, China ). The cells were grown as monolayers in RPMI -1640 ( Gibco, Grand Island, NY ) with 10% calf serum ( Shijiqing Biological Products, Beijing, China ), 100 U /mL penicillin, and 100 g/mL streptomycin in a humidified atmosphere with 5% CO 2 . Both immunohistochemistry and fluorescence -activated cell sorting (FACS ) analyses proved the high expression of p185 on the SGC7901 cell line. MKN -7, an adenocarcinoma gastric cancer cell line that has been well known for the high expression of p185, 27 was kindly provided by M.J. Farthing (Royal London School of Medicine, London, UK ).
Animals
BALB /c nude mice, 4 to 6 weeks old, were provided by Shanghai Cancer Institute for the in vivo tumorigenicity study. They were maintained under specific pathogen -free conditions. Plasmids pSV2 -erbB2 and pSV2 -neo were generous gifts from Professor M. Huang (Anderson Cancer Center, Houston, TX ). The whole 4.4 -kb human c-erbB -2 cDNA sequence was included in the vector pSV2 -erbB2. Mammalian expression vector pDor-neo was provided as a gift from Dr. Hao ( Wu National Medical Academy of China, Beijing, China ).
Cell transfection
Cell transfection was carried out by Lipofectamine ( Gibco ) following kit instructions. In brief, 3Â10 5 cells were placed in a 33 -mm -diameter plate until they became about 80% subconfluent after 24 hours of incubation. Then, the complete medium was replaced with 1 mL serum -free medium ( DMEM; Gibco ) containing 1 g DNA and 12 L Lipofectamine, incubated at 378C for 5 hours before adding 1 mL of medium containing 20% fetal bovine serum, and incubated for another 15 to 20 hours until changed with the complete medium. During selection with G418 ( Sigma Chemical, St. Louis, MO ), the transfected cells were put in a 24-well plate at different concentrations with a G418 concentration of 400 g /mL and incubated for 3 weeks. Mixed colonies were chosen for further study. The transfected cell lines of pDor-RZerb2 and pDor-neo were named SGC /RZ and SGC /Neo, respectively.
In vitro cleavage reaction
To generate the substrate for the ribozyme, a 0.8-kb erbB2 fragment, obtained by digestion of PstI and EcoRI, was inserted into the in vitro transcription vector pGEM3Zf( À ) after the SP6 promoter. This recombinant was designated pGEM -erbB2. We linearized the in vitro transcription vector pGEM -RZerb2 with SalI and the 70-nt RZerb2 was produced by T7 RNA polymerase with the Riboprobe Gemini System II kit (Promega, Madison, WI ) in the presence of 32 P -UTP. At the same time, the in vitro transcription vector pGEM -erbB2 was linearized by PVUII (a restriction site on 2556 of the c -erbB -2 cDNA ). Then, the 334 -nt target RNA was transcripted through the SP6 RNA polymerase. Both the RZerb2 and the substrate RNA transcripts were subjected to polyacrylamide gel electrophoresis (PAGE ) and purified after recovery. The in vitro cleavage reaction was performed with a 10:1 molar ratio of RZerb2 / target RNA. The reaction buffer contained 10 mmol / L MgCl 2 and 50 mmol /L Tris -HCl, pH 7.4. The control group contained only the substrate or RZerb2 and the same buffer. After reaction, samples were analyzed by PAGE and autoradiography.
Probe preparation
The c-erbB -2 antisense RNA probe was made by in vitro transcription. The substrate construct pGEM3Z / 0.8 was linealized by HindIII. Then, transcription was carried out by T7 polymerase in the presence of 32 P -UTP to obtain the 0.8-kb radioisotope -labeled c -erbB -2 antisense RNA.
To generate the RZerb2 probe, we linealized the in vitro transcription vector pGEM -RZerb2 with EcoRI and the 100 -nt RZerb2 antisense RNA was produced by SP6 RNA polymerase in the presence of 32 P-UTP ( Riboprobe Gemini System II kit; Promega).
RNA extraction and hybridization
The total cellular RNA of the transfected cells was extracted by acid guanidinium thiocyanate -phenol -chloroform method. Part of each sample was used to determine absorbance and, hence, the total RNA concentration. Another part was charged on the agarose gel to confirm its integrity. For the rest, equal amounts ( 25 g ) were used for agarose gel electrophoresis followed by agarose gel in situ hybridization 28 to detect the c -erbB -2 mRNA expression. Briefly, baking the gel at 808C incubator for 8 hours, the dry gel was hybridized to the radioactive probes described above and then exposed to film (Eastman Kodak, Rochester, NY ) for 24 hours at À 208C.
In RZerb2 RNA expression dot blot, equal amounts (25 g) of total denatured RNA were loaded on nitrocellulose membrane, followed by three 2-fold serial dilutions. After hybridization with radioisotope -labeled RZerb2 probe, the membrane was also exposed to film for 24 hours at À 208C. Vector pDor-RZerb2 was taken as a positive control during the blot.
Flow cytometric analysis
The p185 levels were quantified by FACS. Cells were trypsinized and washed twice with PBS. Cells ( 1Â10 6 ) were resuspended in 100 L of PBS containing 1:200 diluted primary anti -p185 antibody c-neu ( Zhongshan for Biotechnology, Beijing, China ). After 30 minutes of incubation at room temperature, the cells were washed twice with PBS and then incubated for 30 minutes at room temperature with another 100 L of PBS containing 1:100 diluted fluorescein -labeled goat anti -mouse IgG. After washing with PBS again, the cells were resuspended in 200 L of PBS and analyzed for fluorescence by FACS (Beckman Coulter, Miami, FL ). Fluorescence intensity for the p185 was calibrated using the known protein overexpressed in this cell line recognized by mouse anti -human monoclonal antibody MGb2 ( prepared by our laboratory ). 29 Gastric cancer cell MKN -7 served as a positive control and normal mouse IgG was used as a negative control.
Cell growth rate
To study cell growth rate, cells were seeded at a density of 3Â10 4 in 24 -well plates in complete medium with 1% calf serum. Triplets of each cell line were counted daily from postseeding days 1 to 12. Means ±SE are reported.
Animal study
Female athymic ( nude ) BALB /c mice 4 to 6 weeks old were anesthesized, and transfected SGC7901 clones were injected subcutaneously in a volume of 100 L of 2Â10 7 / mL cells. The mice were maintained under standard pathogen -free conditions and observed daily for evidence of tumor burden. Mice were euthanized with alcohol after 4 weeks, and tumors were measured. Tumor volume was determined by the formula: (lengthÂwidth 2 )/2.
RESULTS
Design of c -erbB -2 -specific ribozyme
The total c-erbB -2 mRNA is 4473 bases. 1 The secondary structure analysis by computer indicated that there are two strong palindromes in this sequence. The first one is between 2418 to 2427 (UCCAGUGGCC ) and 2777 to 2786 (GGCUGCUGGA ). The second one is between 2808 to 2819 ( UGCAGAUGGGGG ) and 3005 to 3016 ( CCCCCAUCUGCA ). The two strong palindromes make the two regions ( 2428 to 2776, 2820 to 3004 ) relatively stable. They are, theoretically, the ideal attacking regions for ribozymes. According to the hammerhead structure, 24 the consensus sequence for ribozyme cleaving is 5 0 -NUX -3 0 sequence (N is any nucleotide and X is either A, U, or C). Among the hundreds of potential sites in the above regions, computer analysis showed that the ideal sites were 2438, 2477, and 2751 because the three sites can easily form the necessary hammerhead structure with the predicted ribozymes. 30 We chose the 2438 site to generate our hammerhead ribozyme and designated it as RZerb2. Its designed sequence is as follows: 5 0 -UUUCCCUCCUGAUGAGUCGUGAGACGAAACACU-UUGAU -3 0 . Its expected secondary structure with the targeting substrate is shown in Figure 1A .
Generation of constructs
The Figure 1B . 
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In vitro cleavage reaction
Both the substrate and the ribozyme were produced by in vitro transcription in the presence of 32 P -UTP. Then, they were purified by 6% denatured polyacrylamide gel. The in vitro cleavage reaction was performed with a 10:1 molar Figure 2 . In vitro cleavage of c -erbB -2 mRNA substrates by hammerhead ribozyme RZerb2. Both the substrate and the ribozyme were produced by in vitro transcription in the presence of ratio of ribozyme /target RNA. The control group contained only substrate or RZerb2 in the same buffer. The reaction was carried out at 378C for 1 hour and analyzed by PAGE and autoradiography. The results ( Fig 2 ) showed that the ribozyme cleaved the 334-nt substrate into 213-and 121-nt portions. Image density analysis demonstrated that 79.3% of substrate was cleaved by the ribozyme in only 1 hour. This result proved that the designed erbB -2-specific ribozyme is very efficient.
Detection of RZerb2 expression by RNA dot blot
After transfection, we screened the transfectants with G418 ( 400 g /mL ). To prove the expression of the RZerb2 in SGC /RZ, we isolated the total cellular RNA of the transfectants and took the radioisotope -labeled RZerb2 probe to perform the RNA dot blot. Figure 3 shows that SGC /RZ had a clearly positive outcome. pDor-RZerb2 was taken as a positive control in the blot.
c -erbB -2 mRNA and protein expression
To verify whether the ribozyme RZerb2 affects c-erbB -2 mRNA expression, we quantified the c -erbB -2 mRNA with in situ agarose gel hybridization. First, we extracted the RNA from the transfectants and the parental cell line. Then, 25 g of total RNA was loaded in running denatured agarose gel. Following the steps of the in situ agarose gel hybridization, BI, FAN, HUI, ET AL: c -erbB -2 RIBOZYME INHIBITS THE MALIGNANCY OF GASTRIC CANCER CELL we found that the signal of c -erbB -2 mRNA in the transfected cells SGC /RZ was greatly diminished compared with that of SGC /Neo and the parental cell line SGC7901 ( Fig 4 ) . This phenomenon suggests the strong cleavage effect of the RZerb2 in the transfectants.
In consensus with the RNA in situ agarose gel hybridization, p185, the c -erbB -2 product, was also changed dramatically from FACS (Fig 5 ) . The outcome of the transfected cells SGC /RZ was down to 28.5%, whereas the parental cell line SGC7901 had a high expression of p185 ( 63.2% ); the control transfectants SGC /Neo was almost not affected. The decrease of the c -erbB -2 product in the RZerb2 transfected cells found the basis for the inhibition of other malignant phenotypes.
Cell growth rate
One of the important functions of the c -erbB -2 product is the stimulation of cell growth. So the change of p185 should affect the growth of the gastric cancer cell line SGC7901. In fact, we observed this effect. In a 1% calf serum medium, the growth rates of SGC7901 and the RZerb2 transfected cells SGC /RZ were quite different (Fig 6 ) . The SGC /RZ was much slower than the SGC7901. The inhibition contributed by the RZerb2 was about 50%. Growth of the control cells SGC /Neo was unchanged.
Tumorigenicity study in nude mice
Twenty female athymic ( nude ) BALB /c mice were divided into four groups. The three cell lines were injected subcutaneously ( 2Â10 6 cells ). The mice were observed daily for evidence of tumor occurrence and the size of formed tumors (Table 1) . Although all the mice in the SGC7901 group and the SGC / Neo control group had tumors occurring in 2 weeks, the SGC /RZ -transplanted group had only one tumors occurring in 2 weeks and three in the third week. After 4 weeks, the average tumor size in the SGC /RZ group was much smaller than those of the SGC7901 and SGC /Neo groups ( P <.01 ), indicating the inhibition of the tumorigenicity of SGC /RZ in nude mice.
DISCUSSION
The finding that ribozymes have RNA catalytic activity is an important progress in gene therapy. Unlike antisense RNA that binds to its substrate, ribozymes can cleave a substrate at a specific site and can be reused after this cleavage. 24 So ribozymes have an advantage compared with antisense RNA. Of the few types of ribozymes already found, the hammerhead ribozyme has caught much attention because of its simple structure and efficient catalytic activity 25 and has been widely used to study infectious disease and malignancy.
In the construction of the ribozyme, the first and most important step is the design of the ribozyme. Theoretically, the consensus cleavage sites for hammerhead ribozyme are 5 0 -NUX -3 0 , 24 but some sites may have higher cleavage efficiency. At least the following three factors contribute to the selection of a site. (a ) The structure of the substrate, especially the secondary structure around the cleavage site, surely affects the function of the ribozyme. (b ) The intrinsic structure of the ribozyme itself. Some designed ribozymes cannot form the hammerhead structure with its substrate because of its intrinsic secondary structure. ( c) The number of nucleotide for the two arms of the ribozyme. Specificity may be affected by fewer nucleotides, but the longer arms may affect the dissociation of the ribozyme from its substrate to decrease the reuse of the ribozyme. In c -erbB -2 mRNA, although hundreds of cleaving sites exist, not every site can be effectively targeted. With computer assistance, we found three ideal targeting sites in two strong palindromes in this sequence; they are located at 2438, 2477, and 2751. In our study, we chose the site 2438 to generate our hammerhead ribozyme. Our design withstood subsequent in vitro and in vivo tests.
According to the original study, the ideal temperature for the hammerhead ribozyme to perform its function is 608C. But in vitro cleavage at the 608C raised question about whether the designed ribozyme would work in vivo. Our in vitro cleavage reaction at 378C still performed excellently. The ribozyme RZerb2 cleaved 79.6% of the substrate in 1 hour. This finding supports the possible use of the ribozyme in vivo.
As we know, c-erbB -2 oncogene product p185 is a member of the epidermal growth factor tyrosine kinase receptor family. Although its natural ligand is not clear, there is evidence that it can strongly promote the growth of malignant cells that overexpress p185. The NIH 3T3 cell can be transformed by the overexpression of c -erbB -2.
5,6 RALT, a mitogen -induced signal transducer that binds to the c -erbB -2 kinase domain, can sustain the mitogenic and transforming activity of c -erbB -2. 32 Recently, a cerbB -2 ribozyme was proved to be rate -limiting in ovarian cancer. 33 Here, we showed the effect of a c -erbB -2 -specific hammerhead ribozyme on gastric cancer cell line SGC7901. Apart from the excellent performance of RZerb2 in vitro, it also decreased c -erbB -2 mRNA and the production of p185. Therefore, as expected, the RZerb2 inhibited cell growth rate of the transfected cells SGC /RZ and its tumorigenicity in nude mice. All these data suggest that c-erbB -2 plays a significant role in malignant phenotypes of the gastric cancer cell line SGC7901 and that the c -erbB-2-specific ribozyme RZerb2 has a positive effect on the reversion of the malignancy of SGC7901.
To summarize our study, the c-erbB -2 -specific ribozyme RZerb2 is very efficient both in vitro and in vivo. This also suggests that c -erbB -2 plays an important role in the growth and development of the SGC7901 cancer cell line and p185 can be a good target for gene therapy. The c -erbB -2 -specific ribozyme RZerb2 may have potent usefulness for gene therapy studies of cancer.
